New hope for liver transplant patients with serious bile duct damage
NCT ID NCT07305363
Summary
This study is testing whether the drug seladelpar can help liver transplant patients who develop ischemic cholangiopathy, a serious complication that damages bile ducts. Ten adult transplant recipients will take the medication daily for one year. Researchers will check if it reduces liver inflammation markers and helps preserve the transplanted liver's function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT; COMPLICATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.